Terms of the deal have not been disclosed.
Kapa Biosystems offers genomic tools for the life sciences sector, which will be used to apply proprietary technologies to enhance enzymes for next-generation sequencing (NGS), as well as polymerase chain reaction (PCR) and real-time PCR applications.
Roche Diagnostics division COO Roland Diggelmann said: "This acquisition builds on Roche’s commitment to develop a differentiated NGS portfolio that will provide our customers with a complete genetic testing solution.
"Kapa’s technology and products complement our current expertise and offerings such as the portfolio of target enrichment products for NGS. "
Kapa’s proprietary protein engineering technology helps in the generation and screening of large numbers of enzyme variants.
The firm’s NGS reagents include enzymes such as novel DNA polymerases that can improve the performance of the entire sequencing workflow.
Kapa Biosystems co-founder and chief scientific officer Paul McEwan said: "Joining Roche provides us access to their broad product portfolio, global reach and clinical expertise that will accelerate our strategy of offering comprehensive NGS workflow solutions to more laboratories around the world."
